Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This entry refers to a human pseudogene, the "leucine rich repeat containing 8 family member B pseudogene" (LOC100421775, ENSG00000237115). Pseudogenes are genomic sequences similar to known genes but lack the ability to encode functional proteins due to mutations or lack of regulatory sequences. There is no evidence that this pseudogene encodes a receptor, enzyme, or other functional molecular target relevant for pharmacological modulation. As such, it is not considered a therapeutic target, nor is it associated with specific biological functions or disease roles. The naming overlap with leucine-rich repeat–containing or T cell–associated proteins is incidental, and there may be confusion with truly functional genes (such as LRCH1 or LRR-containing receptors) which are involved in immune signaling[3][1]. However, this particular entry is a nonfunctional gene and does not serve as a target for drug development or as a biomarker in clinical applications. - This gene is not a drug target and does not encode an active protein product[3]. - Results mentioning leucine-rich repeat proteins in T cell activation (such as LRCH1[1]) refer to different, functional genes/proteins and not to this pseudogene. - If a drug discovery effort or biological study refers to this entity as a target, it is likely a case of misannotation or confusion. If you require information about **functional leucine-rich repeat–containing receptors or immune proteins (e.g., LRCH1)**, these are distinct from this pseudogene and have immunological relevance[1][3]. For LRCH1 and related functional immune proteins, see specific literature for T cell regulation and immune signaling roles[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Leucine rich repeat containing 8 family member B pseudogene.